Email Address
Please enter your official email address
We notice that your permissions preference cookie is missing. Please enter your email address so we can determine if you need to complete a permission form or verify that you have already completed this form. Receiving permission from our users is an important part of our compliance with international privacy regulations. Your email address will not be shared without your permission. Please refer to our
privacy policy
for information on how we protect your personal information.
Welcome to AdisInsight
We need some information from you before you start using the platform.
This information will allow us to better understand how AdisInsight is being used.
It does not require or replace the individual login accounts that many of you use to save searches and create email alerts.
Protecting your personal information is important.
That is why AdisInsight collects the minimum amount of information necessary to enable functionality, report usage, and contact you with information about AdisInsight.
For further information on how we protect and process your personal information, please refer to our
privacy policy.
Terms of Service
By accessing or using the AdisInsight platform you agree to the terms of use.
Please select terms of use
How much you and your colleagues use AdisInsight often determines if your organization will continue paying to provide access to the platform.
The number of times you access AdisInsight, the number of searches you performed, and the number of profiles you viewed will be provided to your organization both in aggregate with other users and individually by your email address.
You have the right to opt-out of sharing your email address with your organization but doing so may negatively affect your organization’s decision to renew their subscription to AdisInsight. If you opt-out your email will still be collected for registration purposes.
Please choose your email permissions
Get more from AdisInsight
Keep up to date with all things AdisInsight by signing up to receive our product bulletin, which includes related content from Springer Nature such as white papers, product news, industry commentaries, and webinar invites, straight to your inbox. Unsubscription is always possible via email.
Developer
Beijing CC-Pharming; iBio Inc; Texas A&M University
Class
COVID-19 vaccines; Synthetic vaccines; Viral vaccines; Virus-like particle vaccines
Mechanism of Action
Immunostimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
No
New Molecular Entity
No
Highest Development Phases
Preclinical
COVID 2019 infections
Most Recent Events
09 Apr 2020
iBio signs a Memorandum of Understanding with the Infectious Disease Research Institute for IBIO 200
26 Mar 2020
Preclinical trials in COVID-2019 infections (Prevention) in USA (unspecified route)
26 Mar 2020
iBio plans clinical development for COVID-2019 infections
Development Overview
Introduction
IBIO 200 is a virus-like particle (VLP) based vaccine being developed by iBio and Beijing CC Pharming using iBio's FastPharming System™, for the prevention of COVID-2019 infections. The vaccine is designed to maximise uptake by antigen presenting cells in order to increase the overall immune response. A SARS-CoV-2 derived antigen is fused to a self-assembling protein partner to generate the VLP. The antigen is displayed in a repetitive structure and geometry, and the particle is decorated with oligomannose molecules to resemble the structure of a naturally occurring virus.FastPharming System™ combines vertical farming, automated hydroponics, and glycan engineering technologies wherein plants are used as bioreactors for development of vaccines and biologics. Preclinical development is underway in the US. Early research is underway in China.
Company Agreements
In February 2020, iBio and Beijing CC Pharming entered into a collaboration to develop and test a new coronavirus vaccine to be manufactured using iBio’s FastPharming System™. Financial terms of the deal are undisclosed.[1][2]
In April 2020,iBio signed a Memorandum of Understanding (MOU) with the Infectious Disease Research Institute (IDRI) to support iBio’s SARS-CoV-2 Virus-Like Particle (VLP) vaccine development. The MOU calls for iBio and IDRI to establish a separate, additional agreement within the next 60 days if iBio opts to include one of IDRI’s adjuvants in the COVID-19 vaccine development programme (IBIO 200). The MoU integrates IDRI into iBio’s collaboration with the Texas A&M University System to create a strong partnership that brings deep experience and advanced technologies and capabilities to the task of moving IBIO 200 into the clinic.[3]
In June 2016, Texas A&M University System entered into a development agreement with iBio for collaborative program in plant-produced pharmaceuticals. The collaboration will use the research and development resources of TAMUS with the commercial therapeutics and vaccine development and manufacturing capabilities of iBio.[4]
Key Development Milestones
In March 2020, iBio initiated preclinical studies of IBIO 200 at the Texas A&M University System (“TAMUS”) laboratories as part of the Master Joint Development Agreement established between iBio and TAMUS[5].
As of February 2020, plant based coronavirus vaccine is in early research for the treatment of COVID-2019 infections[1].
Patent Information
In March 2020, iBio filed four provisional patent applications number US9 012 199 with the U.S. Patent and Trademark Office (US PTO), for Virus Like Particle (VLP) platform technology and lichenase carrier immunostimulatory (“LickM”) adjuvant technology. The applications also cover vaccine manufacturing method using FastPharming system™[6].
Drug Properties & Chemical Synopsis
Formulation
Injection
Class
COVID-19 vaccines, Synthetic vaccines, Viral vaccines, Virus-like particle vaccines
iBio signs a Memorandum of Understanding with the Infectious Disease Research Institute for IBIO 200 [3]
Updated 15 Apr 2020
26 Mar 2020
Phase Change - Preclinical
Preclinical trials in COVID-2019 infections (Prevention) in USA (unspecified route) [5]
Updated 01 Apr 2020
26 Mar 2020
Trial Update
iBio plans clinical development for COVID-2019 infections [5]
Updated 01 Apr 2020
11 Mar 2020
Patent Information
iBio files for patent protection with the US PTO for Virus Like Particle (VLP) platform technology and lichenase carrier immunostimulatory (LickM) adjuvant technology for development of COVID-2019 vaccines in USA [6]
Updated 14 Aug 2020
11 Feb 2020
Phase Change
Early research in COVID-2019-infections (Prevention) in USA (unspecified route)
Updated 11 Feb 2020
06 Feb 2020
Phase Change
Early research in COVID-2019-infections (Prevention) in China (unspecified route) [1]
Updated 11 Feb 2020
03 Feb 2020
Licensing Status
iBio and Beijing CC Pharming agree to co-develop coronavirus vaccine for COVID-2019 infections [1]
Updated 14 Aug 2020
13 Jun 2016
Licensing Status
iBio and Texas A&M University agree co-develop vaccines [4]
Updated 01 Apr 2020
References
iBio and CC-Pharming Initiate Joint Development of Coronavirus Vaccine.
